FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud
Title
FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud
Identifier
/unibl/sci/idNaucniRad:25131
Type
See all items with this valueAcademic Article
Date
Bibliographic Citation
J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016
page start
10
page end
10
Is Part Of
See all items with this valueANNALS OF THE RHEUMATIC DISEASES
See all items with this value0003-4967
list of authors
Position: 5667 (37 views)